#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Steve Flores Email
VP, Supply Chain . Elicio Therapeutics
How to contact Steve Flores
Join and see Steve's contact info for free!Current Roles
Employees:
50Revenue:
$7.8MAbout
Elicio is committed to transforming the lives of patients and their families by re-engineering the body's immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center†of the immune response, to significantly amplify and enhance the body's own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. Elicio's lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio's Amphiphile vaccines target and concentrate in the lymph nodes resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.Elicio Therapeutics Address
451 D StreetCambridge, MA
United States